INTRODUCTION
Glucagon has been known to be a potent stimulant of glycogenolysis (1) and gluconeogenesis (2) , but only recenitly has the physiology of endogenous glucagon been defined (3) . By employing radioimmunoassay (RIA)' procedures with a high degree of specificity for pancreatic glucagon, it has been established that glucagon secretion is suppressed by high blood glucose concentrations and stimulated by hypoglycemia (4, 5) , amino acids such as arginine (6) and alanine (7, 8) , and by exercise (9) , infection (10) , and anxiety (11) . The concept that glucagon secretion plays a significant role in glucose homeostasis is now generally accepted.
Only a few data are available concerning glucagon secretion in the neonatal period, a time of acute energy need. The transition from the intrauterine to an extrauterine environment is characterized by a transient fall in plasma glucose levels, which is not due to lack of several gluco-homeostatic hormones. Moreover, plasma insulin concentrations are low and insulin secretion after stimulation is obtunded (12) . There is evidence that gluconeogenesis is deficient in the newborn (2, 12, 13) , and it is possible that this deficiency may be related to inadequate glucagon secretion. Although this 1 Abbreviationzs used in this paper: GLI, glucagon-like immunoreactivity; RIA, radioimmunoassay. hormone has been identified in the feal pancreas (14) and in the plasma of the human fetus and newborn (14) (15) (16) (17) , the The RIA system using antiserum GL-5 per.mits detection of 10 pg crystalline pork glucagon and cross reacts minimally with the gut extract. In addition, (Fig. 2 ) this system give displacement curves which are essentially identical in both sensitivity and specificity to Dr. Unger's 30K antiserum, widely used and considered specific for glucagon (3, 8, 10) .
Plasma from a volunteer undergoing arginine stimulation gave a reading of 583+29 pg/ml with GL-1 antiserum in seven separate assays; the value with GL-5 antiserum in six separate assays was 450+39 pg/ml (P < 0.01). Thus, assays with GL-1 antiserum overestimate pancreatic glucagon concentration. GL-1 antiserum was used in the crosssectional and arginine stimulation studies; -GL-5 antiserum was used in all other glucagon determinations.
In the assay, 200-,ul plasma samples are reacted with 100 ,ul antibody in a 1: 300,000 final dilution, 50 ,ul Trasylol, (500 U), 100 ,ul 0.1 M EDTA, and 450 ,ul phosphate saline buffer (0.01 M, pH 7.4 with 0.25% normal rabbit serum added). Throughout incubation the protein concentration in the standard curve is controlled with pancreatectomized dog plasma which gave near zero readings in the RIA. Addition of ['SI] glucagon, 20 pg in 100 ,ul, is delayed 48 h after which the reaction is incubated for an additional 72h at 4°C. Free and bound hormones were separated by using a second antibody (goat anti-rabbit antiserum). The 
RESULTS

Iximated 4% in the mid portion of the standard
Cross-sectional studies (Fig. 3) . Glucose declined The interassay coefficient of variation is 13% for from a mean (±SEM) of 77+6 mg/100 ml at i h after erum GL-1 and 23% for antiserum GL-5. birth to 57±5 mg/100 ml at 1 h (P<0.02) and by ident's t test and paired t analysis were used to deterh to 57±4 oss reaction with "gut" glucagons are almost identical using both the GL-1 and GL-5 antisera (Table I) . r. Unger's 30K antiserum, considered specific for pancre-The mean value for total GLI was 2,983±449 pg/ml, changes in glucose and glucagon occurred within the first 2 h after birth. er, there was no
The plasma glucose, insulin, and glucagon concenvalues (r = 0.27; trations on days 1, 2, and 3 are shown in Fig. 5 . Plasma glucose concentration increased from 44±5 mg/100 ml changes in plasma on day 1 to 61±5 mg/100 ml on day 2 (P < 0.05) )ngitudinal studies and 61±6 mg/100 ml on day 3 . In each individual infant, the blood glucose concentrationi was higher on days lucose fell rapidly 2 or 3 of life than on day 1. The plasma insulin level was similar on days 1, 2, and 3. In contrast, the plasma glucagon level was appreciably higher on days 2 and 3 than on day 1 (P < 0.01), and paired t analysis showed agon and Pancreatic that both the 1-2 day change and the 1-3 day change FIGURE 5 Sequential changes in glucose, glucagon, and insulin in eight infants each of whom was sampled at approximately 24, 48 , and 72 h after birth. The increments in glucose and glucagon are significantly correlated (r= 1.0; P < 0.01).
were significant (P < 0.05, P < 0.005, respectively). The changes in mean glucose and glucagon from day 1 to day 2 were highly correlated (r = 1.0; P < 0.01). Individual glucose and glucagon concentrations were correlated only on day 1 (r = -0.91; P < 0.01 ). Stimulation studies: Arginine infusion into the umbilical vein (Table II) did not change blood glucose appreciably, but the mean plasma insulin level increased in an erratic fashion in some, but not all, of the infants studied. In contrast, the glucagon response was dramatic; mean plasma glucagon levels were significantly increased at 30 and 60 min (in comparison to control values P < 0.05); by paired t analysis the differences at 30 and 60 min were even more significant (P < 0.005).
The results of the alanine infusion tests are shown in Table III . Glucose concentrations at 30 min were significantly greater than the mean value before infusion. Plasma insulin also tended to increase; the mean concentration was significantly greater than the baseline value at 60 min (P < 0.05) and by paired t analysis the maximal increment above basal also was significant (P < 0.05).
The mean glucagon level, too, was significantly elevated at 60 min (P < 0.05) and the mean maximal increment above the basal concentration was 128 pg/ml, highly significant by paired t analysis (P < 0.005).
Thus, alanine evoked significant increments in blood glucose, insulin, and glucagon concentrations. However, the incremenits in glucose and insulin were small in comparison to the glucagon response. DISCUSSION The initial fall in blood gluicose with subsequent return to euglycemic levels by days 2-3, as well as the sluggishness of insulin secretion in fetal and newborn humans, primates, and other animiifals miiodels is well documented in the literature (20) (21) (22) (23) (24) (25) (26) (27) (28) . Plasma glucagon concentrations in the present studies were observed to increase during the first 2 h of life in infants studied both cross-sectionally and longitudinally. Both the absolute concentrations and the magnitude of the early increase were similar to those recently reported by Bloom and Johnston in a series of infants in whom glucagon concentrations were determined in cord blood and once again in peripheral plasma 2 h after birth (17) . Moreover, the baseline glucagon values in the plasma from close to or in the portal circulation are in the range recently reported by Luyckx, Massi-Benedetti, Falorni, and Lefebvre in newborn portal plasma (15) . The present results suggest that the pancreatic islet alpha cell in the newborn is capable of responding to the fall in plasma glucose during the first 2 h of life. Although this increment in blood glucagon is statistically significant and correlates well with the fall in blood glucose, it is, in absolute terms, quite small, especially when compared to the dramatic rise -in glucagon found in the early postnatal period in the rat (29) . It is conceivable that this initial rise in glucagon prevents the further fall of glucose. But it is apparently inadequate to evoke appropriate glycogenolytic and gluconeogenic responses in order to raise glucose, since glucagon in pharmacologic doses is capable of increasing glucose concentrations in human newborns (30) and has been shown to activate key gluconeogenic liver enzymes in rats (31) (32) (33) . However, the plasma concentrations achieved with pharmacologic doses of glucagon may exceed the secretory capacity of the neonatal pancreas.
A progressive and more significant increment in basal plasma glucagon concentration occurs between day 1 and day 3 of life; mean plasma glucagon level on the third day of life is 2-3 times the values seen on day 1 of life. This secondary rise is accompanied by, and correlated with, a significant rise in blood glucose concentrations, without alteration in the mean circulating plasma insulin level. It is thus possible that on day 1 the secreted glucagon may be incapable of evoking an appropriate glycemic response by virtue of immaturity of liver glycogenolytic and gluconeogenic enzymes. Reisner et al. (13) have recently reported that in newborn infants pharmacologic doses of glucagon are more effective in activating spanchnic gluconeogenic mechanisms on day 3 than on day 1 of life. These authors suggest that the Significance of Glucagon Secretion in the Human Newborn (34) . No consistent rise in plasma insulin was noted in our studies, and the physiologic significance, if any, of the high plasma GLI concentrations after feeding in infants is not clear.
The dramatic rise in immunoreactive glucagon concentration after arginine infusion suggests that the islet alpha cell in the newborn responds more briskly to this amino acid stimulus than to spontaneous hypoglycemia. In the absence of prior feeding and from the manner of infusion, it is more likely that the increase reflects pancreatic glucagon rather than GLI secretion. And the lack of concommitant rise in glucose may be due to depletion of hepatic glycogen stores and/or the "prehepatic" sampling site.
Our findings that an increase in both glucose and glucagon occurs in response to the infusion of 1 mmol/ kg alanine into a peripheral vein suggests that lack of substrate, or inability to mobilize substrate, may also play a role in the genesis of neonatal hypoglycemia. Alanine was chosen because of its significance as the principal gluconeogenic precursor in what has been called the glucose-alanine cycle (35) , and because it is a known stimulus to glucagon secretion in adults (8) . The glucagon response to both arginine and alanine suggests that the pancreatic islet alpha cell, like the beta cell, is more able at birth to respond to an amino acid signal than a glucose signal (36) .
The present investigations suggest the possibility that botlh relative inadequacy of glucagon secretion and hepatic unresponsiveness to the glucagon signal contribute to the tendency to glucopenia during the first day of life. In .part, the initial sluggishness of the glucagon response to a falling blood glucose may be due to neonatal extension of the observed sluggishness of glucagon secretion in utero (28) , possibly as a result of maternal glucose constantly transported across the placenta. Significantly lower glucagon concentrations have been reported in infants born to diabetic hyperglycemic mothers (11) . The positive correlation between glucose and glucagon concentrations suggests that endogenous glucagon secretion plays a significant role in neonataI glucose homeostasis, particularly on days 2 and 3. However, the negative correlation between glucose and glucagon on day 1, and the glycemic response to alanine imply some hepatic unresponsiveness, relative substrate deficiency, and possibly other factors as being involved in immediate postnatal glucose homeostasis.
